Specifically, SITG significantly reduces brain enzyme levels linked to AD, including AChE, BACE-1, DPP-4, and GSK-3β, while also decreasing inflammatory markers and improving oxidative stress parameters. The gene discussed is ACHE; the disease is Alzheimer disease.